



Zulfiqar A. Malik, MD, PhD

Zulfiqar A. Malik, MD, PhD joined the cancer care team of Northwest Georgia Oncology Centers, P.C. (NGOC) from USMD / Optum Healthcare. He received his medical degree from University of Iowa with Residency completed in Internal Medicine at University of Texas-Southwestern Dallas and Fellowship in Hematology/Oncology at Anderson Cancer Center.

Dr. Malik is actively involved in cancer research and clinical trials to find a cancer cure and provide his patients with the most innovative cancer treatment available in Georgia.

Dr. Malik provides patient-centered cancer care at NGOC's **Marietta Cancer Center**.

Medical Education	MD, PhD, June 2001 University of Iowa Iowa City, Iowa
Postdoctoral	<p>Internship (Internal Medicine) University of Texas-Southwestern Dallas, Texas July 2001 to June 2002</p> <p>Residency (Internal Medicine) University of Texas-Southwestern Dallas, Texas July 2002 to June 2003</p> <p>Fellowship (Hematology/Oncology) MD Anderson Cancer Center Houston, Texas July 2004 to June 2007</p>
Investigator Training	<p>NCI Investigator Protection of Human Subjects Good Clinical Practice: Certification Entity, Completion Date, 2018</p>
Medical Licensure	<p>State of Georgia, Physician License #91031 State of Texas, Physician License #M1221 State of New York, Physician License #286865 State of Kentucky, Physician License #41177 State of Indiana, Physician License #01064364A</p> <p>National Provider Number (NPI): 1841364908 American Board of Internal Medicine, Internal Medicine, 2004 American Board of Internal Medicine, Hematology, 2007 American Board of Internal Medicine, Medical Oncology, 2008</p>
Work History	<p>Staff Physician, Hematology & Oncology Northwest Georgia Oncology Centers, PC Marietta, Georgia 06/2022 to Present</p> <p>Staff Physician, Hematology & Oncology USMD / Optum Healthcare Arlington, Texas 03/2021 to 05/2022 Chief of Research & Staff Physician, Hematology & Oncology</p>

New York Cancer & Blood Specialists
Long Island, New York
03/2017 to 01/2021

Staff Physician, Hematology & Oncology
Norton Cancer Institute
Louisville, Kentucky
08/2007 to 02/2017

Professional Societies Member, Georgia Society of Clinical Oncology

Research Organizations National Cancer Institute

Research Activities MD Anderson Cancer Center
06/2006 - 05/2007
I developed a Phase II study with AZD0530 (Src kinase Inhibitor) in patients with previously treated metastatic colorectal cancer. Mentor Dr. Cathy Eng

University of Iowa
06/1997 - 06/2000
My doctoral thesis examined the mechanisms and outcomes of calcium signaling in human macrophages infected with *M. tuberculosis*. Thesis Advisor: Dr. David Kusner

Chief of Research, New York Cancer & Blood Specialists
03/2018 – 01/2021
I was the principal investigator in over 40 Phase 1-3 clinical trials

Publications Malik, Z.A., Denning, G., and Kusner, D.J.: (2000) Inhibition of Ca²⁺ -Signaling by Mycobacterium tuberculosis is Associated with Increased Survival within Human Macrophages. *J. Exp. Med.* 191:287.

Myung, P.S., Clements J.L., White D.W., Malik Z.A., Cowdery J.S., Allen L.H., Harty J.T., Kusner D.J., and Koretzky G.A. (2000) In vitro and in vivo macrophage function can occur independently of SLP-76. *Int Immunol* 12: 887.

Malik, Z.A. and Kusner, D.J. (2000) Lack of activation of Calmodulin and Ca²⁺/Calmodulindependent Protein Kinase II Contribute to Inhibition of Phagolysosome Fusion and Promotion of the Intracellular Survival of Mycobacterium tuberculosis within Human Macrophages. *J Immunol.* 166:3392

Malik, Z.A., Iyer SS and Kusner, D.J. (2003) Cutting edge: Mycobacterium tuberculosis blocks Ca²⁺ signaling and phagosome maturation in human macrophages via specific inhibition of sphingosine kinase. *J. Immunol.* 170:2811.

Malik, Z.A. and Eng, C., (2007) The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. *Clin Adv Hematol Oncol.* Suppl 1:4

Reddy, SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman M, Fogelman D, Shureqi I, Jacobs C, Malik Z, Jiminez C, Murthy R, Wolff RA, Abbruzzese JL, Gallick G, Eng C, (2015)

Phase II study of Saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer Invest New Drugs. Aug;33(4):977

Principle Investigator on the following Clinical Trials

LOXO-RET-17001 A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation

ANAM-17-20: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non- Small Cell Lung Cancer

APL2-302: A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

ADCT-402-201: A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

D5336C00001: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)

ZL-1201-001. First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer. A study for patients with previously treated advanced or metastatic solid tumors or lymphoma.

A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab in combination with lenvatinib versus docetaxel in previously treated participants with metastatic non- small cell lung cancer and progressive disease after platinum doublet chemotherapy and immunotherapy.

A randomized, prospective, multi-center trial to assess the efficacy of a cryotherapy device versus best supportive oral care in mitigating symptoms of oral mucositis in patients receiving chemotherapy for the treatment of cancer.

ASCENT: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

GTI-4419-301: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese

(GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally- Advanced, Non-Metastatic Head and Neck Cancer

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma

GO27983: Phase Ib/II study of ipatasertib (AKT inhibitor) with zytiga in metastatic castration-resistant prostate cancer

KPG-121-101: A study using KPG-121 plus enzalutamide for patients with Metastatic Castration-Resistant Prostate cancer who's PSA has failed, after 3 months, to respond to treatment with enzalutamide alone.

XL184-021 - A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Protocol CO-338-100. A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated with Deleterious Mutations in Homologous Recombination Repair Genes.

KPG-818-HEM-101. A phase 1 study of lenalidomide analog KPG-818 in subjects with hematologic malignancies. Included diagnoses are: Multiple Myeloma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, and indolent lymphomas

Protocol MK-7339-007: A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer.

Protocol D-US-60010-001: An Open-label, randomised, multicentre, phase III study of Irinotecan liposome injection, Oxaliplatin, 5-fluorouracil/Leucovorin versus Nab- paclitaxel plus Gemcitabine in subjects who have not previously received chemotherapy for metastatic Adenocarcinoma of the Pancreas.

Protocol DZB-CS-201: An open-label multi-cohort Phase 1b/2 study of Derazantinib and Atezolizumab in patients with Urothelial cancer expressing activating molecular FGFR aberrations. Eligible patients will have a mutation in one of the following genes: FGFR1, FGFR2, or FGFR3.

Fibrogen: A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Multiple Myeloma Antibody-drug Conjugate, GSK2857916 (Belantamab Mafodotin) Administered in Combination With Lenalidomide Plus Dexamethasone, or in Combination With Bortezomib Plus Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Sub Investigator
Selected Clinical
Trials:

4-N0056

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

14-N0054

A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer

14-N0039

A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)

14-N0024

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

13-N0178

Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas

13-N0062

A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL TUMOR PRESENT PATHOLOGICALLY IN THE BREAST OR AXILLARY LYMPH NODES FOLLOWING PREOPERATIVE THERAPY

13-N0056

A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

13-N0055

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

13-N0031

RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VERSUS BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA

13-N0012

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's

Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with

Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma

13-N0004

An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)

12-N0231

An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally advanced breast cancer

12-N0142

A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

12-N0086

YOUNG AND STRONG: An Education and Supportive Care Intervention Study for

Young Women with Breast Cancer

11-N0233

Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial

11-N0074

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal

Carcinoma In Situ Resected by Lumpectomy

1124

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

10.0178 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas

Protocol ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tese-taxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

ODO-TE-B201: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane

SPI-POZ-201: A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC

IMMU-132-05: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

DS8201-A-U201: A Phase II, Multicenter, Open-Label Study of DS-8201a, an Anti-

HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who Are Resistant or Refractory to T-DM1

DS8201-A-U301: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS8201A, an Anti-Her2-Antibody Drug Conjugate, Versus Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care

DS8201-A-U302: A Phase 3 Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, an Anti-Her2-Antibody Drug Conjugate, Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

TSR-3000-02-004: Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

KPG-121-101: A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of KPG-

121 in Combination with Enzalutamide in Adult Subjects with Metastatic Castration- Resistant Prostate Cancer

ProSTAR 1205-201: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of

EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

BBI608-303CRC: A Phase III Study of BBI-608 in combination with 5-Flourouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).

CanStem111P: A Phase III Study of Napabucasin (BBI-608) Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

AMO010-301 (ARTIST 1): A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine containing Regimen

Tyme-88-Panc: A Phase II Multi-Center Study of SM-88 in Patients with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy

SPI-POZ-202: A Phase 2 Study of Pozitotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion

Mutation

ZN-e4-001: A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor (EGFR) Mutations

MM-398-01-03-04: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

CX-839-008: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

CX-839-005: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

D4191C00068: An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies

GS-US-313-1580: Dose Optimization Study of Idelalisib in Follicular Lymphoma

BAY 80-6946 / 17833: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL)

OP-103 OCEAN: a randomized, controlled, open-label, phase 3 study of

melflufen/dexamethasone compared with pomalidomide/dexamethasone for patients with relapsed refractory multiple myeloma who are refractory to lenalidomide

LJ401-HH01: A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis (in patients that have been prescribed phlebotomy for greater than 6 months)

ZAM; mlj